FDA debate centers on continuous trials and risk-based early-stage study pathways
FDA debate over clinical trial reform is focused on continuous trials and faster, risk-based pathways for low-risk studies. Recent FDA remarks and existing guidance frame adaptive, seamless designs as compliant if trial integrity is maintained.
Food and Drug Administration Commissioner Marty Makary has been signaling a potential change to how clinical trials are conducted. Since assuming the Commissioner role, he has championed "continuous trials" to accelerate drug development, calling the current phased approach inefficient. Under current FDA practice, virtually all new drug trials are funneled through the same regulatory pathway: a full IND application, GMP-grade manufacturing, and intensive FDA oversight.
Continuous trials is a catchall label for designs that minimize stoppages between phases, adapt in real time to accumulating evidence, and operate under a durable master infrastructure—often using adaptive, seamless, and platform methods. These designs are described as the culmination of decades of innovation, including group sequential monitoring, Bayesian interim decisions, seamless phase 2/3, and master protocols. During COVID-19, large adaptive platform trials demonstrated that the model can accelerate learning at scale.
For decades, the clinical trial process has been defined by distinct, sequential steps: Phase I for safety, Phase II for preliminary efficacy, and Phase III for confirmatory data. Each phase is a separate study, requiring its own protocol, application, and data analysis before the next phase can begin. From the 1970s through the 1990s, interim monitoring and group sequential methods demonstrated that trials could be adapted ethically without inflating error rates, setting the stage for adaptive decision-making. In the early 2000s, Bayesian methods introduced predictive probabilities and continuous monitoring, and seamless phase 2/3 trials normalized carrying data and sites forward across development stages.
Recent FDA remarks and trade coverage frame continuous trials as reducing idle time, decoupling review workstreams, and making phases less siloed. The FDA’s 2019 Adaptive Design Guidance and ICH E20 Step 2 draft in 2025 codify acceptable adaptive methods for confirmatory trials. Any continuous approach must comply with principles on type I error control, trial integrity, and pre-specification.
A parallel argument is that the U.S. makes even the lowest-risk human studies slower, costlier, and more centralized than they need to be. The current one-size-fits-all approach applies equally to a 10-person microdose study and large, late-stage pivotal trials, and reviewer staffing constraints push scarce FDA attention toward low-risk submissions and away from higher-risk inspection and compliance activities, including overseas manufacturing and data-integrity investigations.
As an alternative, the agency could use enforcement discretion to create a fast, risk-based pathway for low-risk early-stage trials. A low-risk trial in Australia can start up in just 4–6 weeks, and the U.K. implemented a notification scheme that allows certain low-intervention trials to proceed within as little as 14 days. These examples are presented as reflecting a common regulatory principle: oversight calibrated to risk.
One proposed framework for low-risk early-stage trials includes accredited IRB oversight with the same oversight and reporting obligations they have today, a streamlined submission comprised of the clinical protocol, investigator’s brochure, and the informed consent form, clear eligibility boundaries excluding higher-risk modalities such as cell and gene therapies, and a rapid, notification-style activation timeline. For small- to mid-sized life sciences companies, the technology required to run continuous trials is described as available today, while broader adoption is tied to rigorous data governance, validation, and auditability.